Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Advanced Medical Solutions Group Cash Ratio?
Advanced Medical Solutions GroupCHIX:AMSL 92 Cash Ratio is 0.36 as of Dec. 2025, which is 90% below its 10-year median of 3.65. GuruFocus rates CHIX:AMSL with a GF Score™ of 92/100 and a GF Value™ of £3.72 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 75.27% on this metric.
Advanced Medical Solutions Group has a Cash Ratio of 0.36. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Advanced Medical Solutions Group's Cash Ratio or its related term are showing as below:
CHIX:AMSl'
s Cash Ratio Range Over the Past 10 Years
Min: 0.36 Med: 3.65 Max: 4.55
Current: 0.36
During the past 13 years, Advanced Medical Solutions Group's highest Cash Ratio was 4.55. The lowest was 0.36. And the median was 3.65.
CHIX:AMSl's Cash Ratio is ranked worse than 75.27% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.98
vs CHIX:AMSl: 0.36
Advanced Medical Solutions Group (CHIX:AMSl) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Advanced Medical Solutions Group Cash Ratio Related Terms
Advanced Medical Solutions Group Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMSL vs ISRG, BDX, MDLN: Cash Ratio Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a Cash Ratio of 0.36 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Advanced Medical Solutions Group and its competitors. This is 90% below median its historical median of 3.65. Over the past decade, Advanced Medical Solutions Group's Cash Ratio has ranged from 0.36 to 4.55. According to the industry distribution chart, Advanced Medical Solutions Group ranks #633 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 75.3%.
Is Advanced Medical Solutions Group's Cash Ratio too high?
Advanced Medical Solutions Group's current Cash Ratio of 0.36 is 90% below median its 10-year median of 3.65. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 4.55. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Advanced Medical Solutions Group's value of 0.36 is 63.3% below this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #633 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Advanced Medical Solutions Group has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Cash Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #633 out of 841 companies for Cash Ratio. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Cash Ratio is 0.98. Advanced Medical Solutions Group's value of 0.36 is 63.3% below this benchmark. Historically, Advanced Medical Solutions Group's own Cash Ratio has ranged from 0.36 to 4.55 over the past decade. While the company's 10-year median is 3.65 vs. the industry median of 0.98, Advanced Medical Solutions Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current Cash Ratio of 0.36 is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Cash Ratio is 0.36, which is 90% below median its own 10-year median of 3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.72, compared to a current price of £2.80 — trading 24.9% below its estimated fair value. The current Cash Ratio is 0.36, which is 90% below median its 10-year median of 3.65 and 63.3% below the Medical Devices & Instruments industry median of 0.98. Advanced Medical Solutions Group's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Cash Ratio is 0.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.80 is trading 24.9% below its estimated GF Value™ of £3.72.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Cash Ratio: 0.36 (90% below median its 10-year median of 3.65)
GF Value™: £3.72 vs. price of £2.80 (24.9% below fair value)
Industry Position: 63.3% below the Medical Devices & Instruments median (#633 of 841)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
92GF Score
Get the complete analysis for CHIX:AMSL
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
